<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54">DNA vaccines, chimeric viral vaccines, and membrane vesicle-vaccines are valuable options [
 <xref ref-type="bibr" rid="CR201">201</xref>]. An mRNA-based vaccine by Moderna
 <sup>®</sup> is believed to develop antibodies against spike proteins of SARS-CoV-2, and a batch of vaccine has been delivered to the National Institute of Allergy and Infectious Diseases. That was developed 42 days after the DNA sequence of SARS-CoV-2 was disclosed. Eli Lilly
 <sup>®</sup> and AbCellera
 <sup>®</sup> are evaluating Antibody-based treatment. GlaxoSmithKline
 <sup>®</sup> has produced a pandemic vaccine adjuvant platform that it is partnering with other institutes and companies for use in COVID-19 vaccine candidates. Concerning this, recombinant DNA vaccines using GSK’s adjuvant are being developed by Sanofi
 <sup>®</sup> in collaboration with GlaxoSmithKline (GSK) and expected to start phase 1/2 clinical study in September 2020 [
 <xref ref-type="bibr" rid="CR222">222</xref>, 
 <xref ref-type="bibr" rid="CR223">223</xref>].
</p>
